Abstract:Both reversible noncovalent inhibitors and irreversible covalent inhibitors targeting tyrosine kinases have their disadvantages. The reversible covalent inhibitors with electrophilic group cyanoacrylamide as warheads reacting with cysteine residues could solve the dilemmas. However, there are still several unresolved issues regarding the electrophilic groups. In this manuscript, a series of EGFR inhibitors with double electron-withdrawing substituents introduced into the C-alpha position on the olefin bond were designed and synthesized. The binding structures and characteristics of inhibitors with the kinase in both the first noncovalent binding phase and the second covalent binding step were explored and combined with molecular docking and molecular dynamics simulations. Then, the reverse beta-elimination reactions of the thiol-Michael adducts were investigated by applying density functional theory calculations. In addition, the effects of different electrophilic substituents of C-alpha on the binding between the inhibitors and kinase were elucidated. The results suggested that the electrophilicity and size of the electron-withdrawing groups play an important role in the specific interactions during the reaction. The compounds with the electron-withdrawing groups that had medium electrostatic and steric complementarity to the kinase active site could cooperatively stabilize the complexes and showed relatively good potent activities in the kinase assay experiment. The mechanical and structural information in this study could enhance our understanding of the functioning of the electron-withdrawing groups in the covalent inhibitors. The results might help to design efficient cysteine targeting inhibitors in the future.

Overcoming Secondary Mutations of Type II Kinase Inhibitors

L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds

Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?

The Prospect of Substrate-Based Kinase Inhibitors to Improve Target Selectivity and Overcome Drug Resistance.

Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent "Type V" Kinase Inhibitors

Combating Drug-Resistant Mutants of Anaplastic Lymphoma Kinase with Potent and Selective Type-I1/2 Inhibitors by Stabilizing Unique DFG-Shifted Loop Conformation.

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation

Integrated in Silico‐in Vitro Analysis of Systematic Kinase Gatekeeper Mutation Effects on Pan‐kinase Inhibitors in Targeted Liver Cancer Therapy

The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations.

Impact of Type II LRRK2 inhibitors on signaling and mitophagy

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

Targeting cancer with small molecule kinase inhibitors

Type-II kinase inhibitors that target Parkinson’s Disease-associated LRRK2

Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases

Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies

Tyrosine kinase inhibitors in cancers: Treatment optimization - Part I

A secondary RET mutation in the activation loop conferring resistance to vandetanib

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia